To page body
university of tampere: biomeditech: publications:
BioMediTechTampereen yliopisto BioMediTech

IBT Publications 2011

NOTE: This list is not exhaustive because it has been collected by an automatic procedure from PubMed. It may also contain publications not related to IBT (formerly IMT or Regea) authors (authors having the same name). The same publication may also appear more than once in case several research groups have participated in the writing.
Bioinformatics
Mauno Vihinen - Bioinformatics Group
Auerbach AD, Burn J, Cassiman JJ, Claustres M, Cotton RG, Cutting G, den Dunnen JT, El-Ruby M, Vargas AF, Greenblatt MS, Macrae F, Matsubara Y, Rimoin DL, Vihinen M, Van Broeckhoven C
Mutation (variation) databases and registries: a rationale for coordination of efforts.
Nat Rev Genet 2011 ;12(12)881; discussion 881
PMID

Dalgleish R, Oetting WS, Auerbach AD, Beckmann JS, Cambon-Thomsen A, Devereau A, Greenblatt MS, Patrinos GP, Taylor GR, Vihinen M, Brookes AJ
Clarity and claims in variation/mutation databasing.
Nat Biotechnol 2011 ;29(9)790-2; author reply 792-4
PMID

Mattila H, Schindler M, Isotalo J, Ikonen T, Vihinen M, Oja H, Tammela TL, Wahlfors T, Schleutker J
NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene.
BMC Cancer 2011 ;11327
PMID

Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, Westermarck J
ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells.
PLoS One 2011 ;6(3)e17979
PMID

Thusberg J, Olatubosun A, Vihinen M
Performance of mutation pathogenicity prediction methods on missense variants.
Hum Mutat 2011 ;32(4)358-68
PMID

Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL
Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Breast Cancer Res 2011 ;13(1)R20
PMID

Laurila K, Vihinen M
PROlocalizer: integrated web service for protein subcellular localization prediction.
Amino Acids 2011 ;40(3)975-80
PMID

Biotechnology
Vesa Hytönen - Protein Dynamics
Markku Kulomaa - Molecular Biotechnology
Linko V, Leppiniemi J, Shen B, Niskanen E, Hytönen VP, Toppari JJ
Growth of immobilized DNA by polymerase: bridging nanoelectrodes with individual dsDNA molecules.
Nanoscale 2011 ;3(9)3788-92
PMID

Heikkinen JJ, Kivimäki L, Määttä JA, Mäkelä I, Hakalahti L, Takkinen K, Kulomaa MS, Hytönen VP, Hormi OE
Versatile bio-ink for covalent immobilization of chimeric avidin on sol-gel substrates.
Colloids Surf B Biointerfaces 2011 ;87(2)409-14
PMID

Bootorabi F, Jänis J, Hytönen VP, Valjakka J, Kuuslahti M, Vullo D, Niemelä O, Supuran CT, Parkkila S
Acetaldehyde-derived modifications on cytosolic human carbonic anhydrases.
J Enzyme Inhib Med Chem 2011 ;26(6)862-70
PMID

Riihimäki TA, Hiltunen S, Rangl M, Nordlund HR, Määttä JA, Ebner A, Hinterdorfer P, Kulomaa MS, Takkinen K, Hytönen VP
Modification of the loops in the ligand-binding site turns avidin into a steroid-binding protein.
BMC Biotechnol 2011 ;1164
PMID

Riihimäki TA, Kukkurainen S, Varjonen S, Hörhä J, Nyholm TK, Kulomaa MS, Hytönen VP
Construction of chimeric dual-chain avidin by tandem fusion of the related avidins.
PLoS One 2011 ;6(5)e20535
PMID

Linko V, Leppiniemi J, Paasonen ST, Hytönen VP, Toppari JJ
Defined-size DNA triple crossover construct for molecular electronics: modification, positioning and conductance properties.
Nanotechnology 2011 ;22(27)275610
PMID

Heikkinen JJ, Riihimäki TA, Määttä JA, Suomela SE, Kantomaa J, Kulomaa MS, Hytönen VP, Hormi OE
Covalent biofunctionalization of cellulose acetate with thermostable chimeric avidin.
ACS Appl Mater Interfaces 2011 ;3(7)2240-5
PMID

Leppiniemi J, Määttä JA, Hammaren H, Soikkeli M, Laitaoja M, Jänis J, Kulomaa MS, Hytönen VP
Bifunctional avidin with covalently modifiable ligand binding site.
PLoS One 2011 ;6(1)e16576
PMID

Nurminen K, Blazevic V, Huhti L, Räsänen S, Koho T, Hytönen VP, Vesikari T
Prevalence of norovirus GII-4 antibodies in Finnish children.
J Med Virol 2011 ;83(3)525-31
PMID

Määttä JA, Eisenberg-Domovich Y, Nordlund HR, Hayouka R, Kulomaa MS, Livnah O, Hytönen VP
Chimeric avidin shows stability against harsh chemical conditions--biochemical analysis and 3D structure.
Biotechnol Bioeng 2011 ;108(3)481-90
PMID

Heikkinen JJ, Kivimäki L, Määttä JA, Mäkelä I, Hakalahti L, Takkinen K, Kulomaa MS, Hytönen VP, Hormi OE
Versatile bio-ink for covalent immobilization of chimeric avidin on sol-gel substrates.
Colloids Surf B Biointerfaces 2011 ;87(2)409-14
PMID

Riihimäki TA, Hiltunen S, Rangl M, Nordlund HR, Määttä JA, Ebner A, Hinterdorfer P, Kulomaa MS, Takkinen K, Hytönen VP
Modification of the loops in the ligand-binding site turns avidin into a steroid-binding protein.
BMC Biotechnol 2011 ;1164
PMID

Riihimäki TA, Kukkurainen S, Varjonen S, Hörhä J, Nyholm TK, Kulomaa MS, Hytönen VP
Construction of chimeric dual-chain avidin by tandem fusion of the related avidins.
PLoS One 2011 ;6(5)e20535
PMID

Heikkinen JJ, Riihimäki TA, Määttä JA, Suomela SE, Kantomaa J, Kulomaa MS, Hytönen VP, Hormi OE
Covalent biofunctionalization of cellulose acetate with thermostable chimeric avidin.
ACS Appl Mater Interfaces 2011 ;3(7)2240-5
PMID

Leppiniemi J, Määttä JA, Hammaren H, Soikkeli M, Laitaoja M, Jänis J, Kulomaa MS, Hytönen VP
Bifunctional avidin with covalently modifiable ligand binding site.
PLoS One 2011 ;6(1)e16576
PMID

Määttä JA, Eisenberg-Domovich Y, Nordlund HR, Hayouka R, Kulomaa MS, Livnah O, Hytönen VP
Chimeric avidin shows stability against harsh chemical conditions--biochemical analysis and 3D structure.
Biotechnol Bioeng 2011 ;108(3)481-90
PMID

Cancer Groups
Jorma Isola - Cancer Biology
Anne Kallioniemi - Cancer Genomics
Tapio Visakorpi - Molecular Biology of Prostate Cancer
Johanna Schleutker - Genetic Predisposition to Cancer
Hans Lilja - Prostate Cancer Biomarkers
Lehtimäki T, Lundin M, Linder N, Sihto H, Holli K, Turpeenniemi-Hujanen T, Kataja V, Isola J, Joensuu H, Lundin J
Long-term prognosis of breast cancer detected by mammography screening or other methods.
Breast Cancer Res 2011 ;13(6)R134
PMID

Kallio H, Tolvanen M, Jänis J, Pan PW, Laurila E, Kallioniemi A, Kilpinen S, Tuominen VJ, Isola J, Valjakka J, Pastorekova S, Pastorek J, Parkkila S
Characterization of non-specific cytotoxic cell receptor protein 1: a new member of the lectin-type subfamily of F-box proteins.
PLoS One 2011 ;6(11)e27152
PMID

Tolonen TT, Kujala PM, Tammela TL, Tuominen VJ, Isola JJ, Visakorpi T
Overall and worst gleason scores are equally good predictors of prostate cancer progression.
BMC Urol 2011 ;1121
PMID

Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M,
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Lancet Oncol 2011 ;12(12)1134-42
PMID

Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, Sailas L, Kataja V, Turpeenniemi-Hujanen T, Isola J, Heikkilä P, Joensuu H
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.
Breast Cancer Res 2011 ;13(5)R87
PMID

Tothova V, Isola J, Parkkila S, Kopacek J, Pastorek J, Pastorekova S, Gibadulinova A
Glucocorticoid receptor-mediated transcriptional activation of S100P gene coding for cancer-related calcium-binding protein.
J Cell Biochem 2011 ;112(11)3373-84
PMID

Tolonen TT, Tammela TL, Kujala PM, Tuominen VJ, Isola JJ, Visakorpi T
Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer.
BJU Int 2011 ;108(9)1430-8
PMID

Barok M, Tanner M, Köninki K, Isola J
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Breast Cancer Res 2011 ;13(2)R46
PMID

Tolonen TT, Kujala PM, Laurila M, Tirkkonen M, Ilvesaro J, Tuominen VJ, Tammela TL, Isola J
Routine dual-color immunostaining with a 3-antibody cocktail improves the detection of small cancers in prostate needle biopsies.
Hum Pathol 2011 ;42(11)1635-42
PMID

Barok M, Tanner M, Köninki K, Isola J
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
Cancer Lett 2011 ;306(2)171-9
PMID

Junttila TT, Tanner M, Isola J
[Targeted cytotoxic drugs emerging for cancer therapy].
Duodecim 2011 ;127(4)343-9
PMID

Konsti J, Lundin M, Joensuu H, Lehtimäki T, Sihto H, Holli K, Turpeenniemi-Hujanen T, Kataja V, Sailas L, Isola J, Lundin J
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer.
BMC Clin Pathol 2011 ;113
PMID

Lassus H, Staff S, Leminen A, Isola J, Butzow R
Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma.
Gynecol Oncol 2011 ;120(1)11-7
PMID

Rodriguez-Martinez A, Alarmo EL, Saarinen L, Ketolainen J, Nousiainen K, Hautaniemi S, Kallioniemi A
Analysis of BMP4 and BMP7 signaling in breast cancer cells unveils time-dependent transcription patterns and highlights a common synexpression group of genes.
BMC Med Genomics 2011 ;480
PMID

Kallio H, Tolvanen M, Jänis J, Pan PW, Laurila E, Kallioniemi A, Kilpinen S, Tuominen VJ, Isola J, Valjakka J, Pastorekova S, Pastorek J, Parkkila S
Characterization of non-specific cytotoxic cell receptor protein 1: a new member of the lectin-type subfamily of F-box proteins.
PLoS One 2011 ;6(11)e27152
PMID

Virtanen S, Alarmo EL, Sandström S, Ampuja M, Kallioniemi A
Bone morphogenetic protein -4 and -5 in pancreatic cancer--novel bidirectional players.
Exp Cell Res 2011 ;317(15)2136-46
PMID

Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, Blomqvist C, Aittomäki K, Bützow R, Nevanlinna H
RAD51C is a susceptibility gene for ovarian cancer.
Hum Mol Genet 2011 ;20(16)3278-88
PMID

Kuuselo R, Savinainen K, Sandström S, Autio R, Kallioniemi A
MED29, a component of the mediator complex, possesses both oncogenic and tumor suppressive characteristics in pancreatic cancer.
Int J Cancer 2011 ;129(11)2553-65
PMID

Siltanen S, Wahlfors T, Schindler M, Saramäki OR, Mpindi JP, Latonen L, Vessella RL, Tammela TL, Kallioniemi O, Visakorpi T, Schleutker J
Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.
PLoS One 2011 ;6(10)e26595
PMID

Tolonen TT, Kujala PM, Tammela TL, Tuominen VJ, Isola JJ, Visakorpi T
Overall and worst gleason scores are equally good predictors of prostate cancer progression.
BMC Urol 2011 ;1121
PMID

Furusato B, van Leenders GJ, Trapman J, Kimura T, Egawa S, Takahashi H, Furusato M, Visakorpi T, Hano H
Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients.
Pathol Int 2011 ;61(7)409-14
PMID

Renkonen R, Björkroth J, Helve O, Louhimo J, Rautava P, Remes A, Seppälä T, Turunen JP, Virjo I, Visakorpi T, Heikinheimo M
[Are there enough medical scientists in Finland?].
Duodecim 2011 ;127(10)1003-9
PMID

Tolonen TT, Tammela TL, Kujala PM, Tuominen VJ, Isola JJ, Visakorpi T
Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer.
BJU Int 2011 ;108(9)1430-8
PMID

Boormans JL, Porkka K, Visakorpi T, Trapman J
Confirmation of the association of TMPRSS2(exon 0):ERG expression and a favorable prognosis of primary prostate cancer.
Eur Urol 2011 ;60(1)183-4
PMID

Porkka KP, Ogg EL, Saramäki OR, Vessella RL, Pukkila H, Lähdesmäki H, van Weerden WM, Wolf M, Kallioniemi OP, Jenster G, Visakorpi T
The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers.
Genes Chromosomes Cancer 2011 ;50(7)499-509
PMID

Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, Westermarck J
ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells.
PLoS One 2011 ;6(3)e17979
PMID

Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T
MicroRNA in prostate, bladder, and kidney cancer: a systematic review.
Eur Urol 2011 ;59(5)671-81
PMID

Waltering KK, Porkka KP, Jalava SE, Urbanucci A, Kohonen PJ, Latonen LM, Kallioniemi OP, Jenster G, Visakorpi T
Androgen regulation of micro-RNAs in prostate cancer.
Prostate 2011 ;71(6)604-14
PMID

Siltanen S, Wahlfors T, Schindler M, Saramäki OR, Mpindi JP, Latonen L, Vessella RL, Tammela TL, Kallioniemi O, Visakorpi T, Schleutker J
Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.
PLoS One 2011 ;6(10)e26595
PMID

Mattila H, Schindler M, Isotalo J, Ikonen T, Vihinen M, Oja H, Tammela TL, Wahlfors T, Schleutker J
NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene.
BMC Cancer 2011 ;11327
PMID

Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, Campa D, Riboli E, Key T, Gronberg H, Hunter DJ, Kraft P, Thun MJ, Ingles S, Chanock S, Albanes D, Hayes RB, Neal DE, Hamdy FC, Donovan JL, Pharoah P, Schumacher F, Henderson BE, Stanford JL, Ostrander EA, Sorensen KD, Dörk T, Andriole G, Dickinson JL, Cybulski C, Lubinski J, Spurdle A, Clements JA, Chambers S, Aitken J, Gardiner RA, Thibodeau SN, Schaid D, John EM, Maier C, Vogel W, Cooney KA, Park JY, Cannon-Albright L, Brenner H, Habuchi T, Zhang HW, Lu YJ, Kaneva R, Muir K, Benlloch S, Leongamornlert DA, Saunders EJ, Tymrakiewicz M, Mahmud N, Guy M, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English DR, Wahlfors T, Tammela TL, Klarskov P, Nordestgaard BG, Røder MA, Tybjærg-Hansen A, Bojesen SE, Travis R, Canzian F, Kaaks R, Wiklund F, Aly M, Lindstrom S, Diver WR, Gapstur S, Stern MC, Corral R, Virtamo J, Cox A, Haiman CA, Le Marchand L, Fitzgerald L, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Meyer A, Serth J, Yeager M, Berndt SI, Marthick JR, Patterson B, Wokolorczyk D, Batra J, Lose F, McDonnell SK, Joshi AD, Shahabi A, Rinckleb AE, Ray A, Sellers TA, Lin HY, Stephenson RA, Farnham J, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V, Easton DF, Eeles RA, , ,
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.
Nat Genet 2011 ;43(8)785-91
PMID

Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, Blomqvist C, Aittomäki K, Bützow R, Nevanlinna H
RAD51C is a susceptibility gene for ovarian cancer.
Hum Mol Genet 2011 ;20(16)3278-88
PMID

Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL
Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Breast Cancer Res 2011 ;13(1)R20
PMID

Cropp CD, Simpson CL, Wahlfors T, Ha N, George A, Jones MS, Harper U, Ponciano-Jackson D, Green TA, Tammela TL, Bailey-Wilson J, Schleutker J
Genome-wide linkage scan for prostate cancer susceptibility in Finland: evidence for a novel locus on 2q37.3 and confirmation of signal on 17q21-q22.
Int J Cancer 2011 ;129(10)2400-7
PMID

Nurminen R, Wahlfors T, Tammela TL, Schleutker J
Identification of an aggressive prostate cancer predisposing variant at 11q13.
Int J Cancer 2011 ;129(3)599-606
PMID

Clauss A, Persson M, Lilja H, Lundwall Å
Three genes expressing Kunitz domains in the epididymis are related to genes of WFDC-type protease inhibitors and semen coagulum proteins in spite of lacking similarity between their protein products.
BMC Biochem 2011 ;1255
PMID

Vickers A, Lilja H
Editorial comment.
Urology 2011 ;78(3)606; author reply 606
PMID

Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
Eur Urol 2011 ;60(5)897-904
PMID

Végvári A, Rezeli M, Häkkinen J, Sihlbom C, Carlsohn E, Malm J, Lilja H, Laurell T, Marko-Varga G
Bioinformatic strategies for unambiguous identification of prostate specific antigen in clinical samples.
J Proteomics 2011 ;75(1)202-10
PMID

Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A
Tumor markers in prostate cancer I: blood-based markers.
Acta Oncol 2011 ;50 Suppl 161-75
PMID

Peltola MT, Niemelä P, Alanen K, Nurmi M, Lilja H, Pettersson K
Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(₁₄₅) or Lys(₁₄₆) from fPSA without internal cleavages at Lys(₁₄₅) or Lys(₁₄₆).
J Immunol Methods 2011 ;369(1-2)74-80
PMID

Gupta A, Lilja H
Editorial comment.
Urology 2011 ;77(4)903-4; author reply 904
PMID

Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
J Natl Cancer Inst 2011 ;103(6)462-9
PMID

Vickers AJ, Gupta A, Savage CJ, Pettersson K, Dahlin A, Bjartell A, Manjer J, Scardino PT, Ulmert D, Lilja H
A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
Cancer Epidemiol Biomarkers Prev 2011 ;20(2)255-61
PMID

Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, Bjartell AS, Scardino PT, Ulmert D, Vickers AJ
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
Cancer 2011 ;117(6)1210-9
PMID

Christensson A, Bruun L, Björk T, Cronin AM, Vickers AJ, Savage CJ, Lilja H
Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
BJU Int 2011 ;107(11)1769-74
PMID

O'Brien MF, Cronin AM, Fearn PA, Savage CJ, Smith B, Stasi J, Scardino PT, Fisher G, Cuzick J, Møller H, Oliver RT, Berney DM, Foster CS, Eastham JA, Vickers AJ, Lilja H,
Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.
Int J Cancer 2011 ;128(10)2373-81
PMID

Cellular Biology
Ari-Pekka Huovila - Cell Interactions
Herma Renkema - Biochemistry of Cell Signaling
Raitoharju E, Seppälä I, Levula M, Kuukasjärvi P, Laurikka J, Nikus K, Huovila AP, Oksala N, Klopp N, Illig T, Laaksonen R, Karhunen PJ, Viik J, Lehtinen R, Pelto-Huikko M, Tarkka M, Kähönen M, Lehtimäki T
Common variation in the ADAM8 gene affects serum sADAM8 concentrations and the risk of myocardial infarction in two independent cohorts.
Atherosclerosis 2011 ;218(1)127-33
PMID

Mitochondrial Genetics
Howy Jacobs - Mitochondrial Gene Expression and Disease Group
Laurie Kaguni - Mitochondrial Biogenesis in Health and Disease
Alberto Sanz - Mitochondrial Gerontology and Age-related Diseases
Hans Spelbrink - Molecular Biology-Mitochondrial DNA maintenance
Rubio-Cosials A, Sidow JF, Jiménez-Menéndez N, Fernández-Millán P, Montoya J, Jacobs HT, Coll M, Bernadó P, Solà M
Human mitochondrial transcription factor A induces a U-turn structure in the light strand promoter.
Nat Struct Mol Biol 2011 ;18(11)1281-9
PMID

Häkkinen A, Healy S, Jacobs HT, Ribeiro AS
Genome wide study of NF-Y type CCAAT boxes in unidirectional and bidirectional promoters in human and mouse.
J Theor Biol 2011 ;281(1)74-83
PMID

Hyvärinen AK, Pohjoismäki JL, Holt IJ, Jacobs HT
Overexpression of MTERFD1 or MTERFD3 impairs the completion of mitochondrial DNA replication.
Mol Biol Rep 2011 ;38(2)1321-8
PMID

Oliveira MT, Kaguni LS
Reduced stimulation of recombinant DNA polymerase γ and mitochondrial DNA (mtDNA) helicase by variants of mitochondrial single-stranded DNA-binding protein (mtSSB) correlates with defects in mtDNA replication in animal cells.
J Biol Chem 2011 ;286(47)40649-58
PMID

Euro L, Farnum GA, Palin E, Suomalainen A, Kaguni LS
Clustering of Alpers disease mutations and catalytic defects in biochemical variants reveal new features of molecular mechanism of the human mitochondrial replicase, Pol γ.
Nucleic Acids Res 2011 ;39(21)9072-84
PMID

Leeuwenburgh C, Pamplona R, Sanz A
Mitochondria and aging.
J Aging Res 2011 ;2011782946
PMID

Stefanatos R, Sanz A
Mitochondrial complex I: a central regulator of the aging process.
Cell Cycle 2011 ;10(10)1528-32
PMID

Pohjoismäki JL, Goffart S, Spelbrink JN
Replication stalling by catalytically impaired Twinkle induces mitochondrial DNA rearrangements in cultured cells.
Mitochondrion 2011 ;11(4)630-4
PMID

Atanassova N, Fusté JM, Wanrooij S, Macao B, Goffart S, Bäckström S, Farge G, Khvorostov I, Larsson NG, Spelbrink JN, Falkenberg M
Sequence-specific stalling of DNA polymerase γ and the effects of mutations causing progressive ophthalmoplegia.
Hum Mol Genet 2011 ;20(6)1212-23
PMID

Molecular Immunology
Dan Hultmark - Genetic Immunology
Marko Pesu - Immunoregulation
Mika Rämet - Experimental Immunology
Olli Silvennoinen - Molecular Immunology
Ekström JO, Habayeb MS, Srivastava V, Kieselbach T, Wingsle G, Hultmark D
Drosophila Nora virus capsid proteins differ from those of other picorna-like viruses.
Virus Res 2011 ;160(1-2)51-8
PMID

Ulvila J, Vanha-aho LM, Kleino A, Vähä-Mäkilä M, Vuoksio M, Eskelinen S, Hultmark D, Kocks C, Hallman M, Parikka M, Rämet M
Cofilin regulator 14-3-3zeta is an evolutionarily conserved protein required for phagocytosis and microbial resistance.
J Leukoc Biol 2011 ;89(5)649-59
PMID

Pesu M
Mutant JAK3 FERMents ATLL.
Blood 2011 ;118(14)3759-60
PMID

Marttila S, Jylhävä J, Pesu M, Hämäläinen S, Jylhä M, Hervonen A, Hurme M
IL-7 concentration is increased in nonagenarians but is not associated with markers of T cell immunosenescence.
Exp Gerontol 2011 ;46(12)1000-2
PMID

Turpeinen H, Raitoharju E, Oksanen A, Oksala N, Levula M, Lyytikäinen LP, Järvinen O, Creemers JW, Kähönen M, Laaksonen R, Pelto-Huikko M, Lehtimäki T, Pesu M
Proprotein convertases in human atherosclerotic plaques: the overexpression of FURIN and its substrate cytokines BAFF and APRIL.
Atherosclerosis 2011 ;219(2)799-806
PMID

Valanne S, Rämet M
[Fruit fly--genetically excellent model animal for research].
Duodecim 2011 ;127(19)2063-71
PMID

Ulvila J, Vanha-Aho LM, Rämet M
Drosophila phagocytosis - still many unknowns under the surface.
APMIS 2011 ;119(10)651-62
PMID

Valanne S, Wang JH, Rämet M
The Drosophila Toll signaling pathway.
J Immunol 2011 ;186(2)649-56
PMID

Ulvila J, Vanha-aho LM, Kleino A, Vähä-Mäkilä M, Vuoksio M, Eskelinen S, Hultmark D, Kocks C, Hallman M, Parikka M, Rämet M
Cofilin regulator 14-3-3zeta is an evolutionarily conserved protein required for phagocytosis and microbial resistance.
J Leukoc Biol 2011 ;89(5)649-59
PMID

Rämet M, Korppi M, Hallman M
Pattern recognition receptors and genetic risk for rsv infection: value for clinical decision-making?
Pediatr Pulmonol 2011 ;46(2)101-10
PMID

Ungureanu D, Wu J, Pekkala T, Niranjan Y, Young C, Jensen ON, Xu CF, Neubert TA, Skoda RC, Hubbard SR, Silvennoinen O
The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.
Nat Struct Mol Biol 2011 ;18(9)971-6
PMID

Sanz A, Ungureanu D, Pekkala T, Ruijtenbeek R, Touw IP, Hilhorst R, Silvennoinen O
Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation.
PLoS One 2011 ;6(4)e18522
PMID

Dong L, Zhang X, Fu X, Zhang X, Gao X, Zhu M, Wang X, Yang Z, Jensen ON, Saarikettu J, Yao Z, Silvennoinen O, Yang J
PTB-associated splicing factor (PSF) functions as a repressor of STAT6-mediated Ig epsilon gene transcription by recruitment of HDAC1.
J Biol Chem 2011 ;286(5)3451-9
PMID

Regenerative Medicine
Katriina Aalto-Setälä - Cardiology Group
Susanna Miettinen - Adult Stem Cell Group
Susanna Narkilahti - Neuro Group
Heli Skottman - Ophthalmology Group
Kujala VJ, Jimenez ZC, Väisänen J, Tanskanen JM, Kerkelä E, Hyttinen J, Aalto-Setälä K
Averaging in vitro cardiac field potential recordings obtained with microelectrode arrays.
Comput Methods Programs Biomed 2011 ;104(2)199-205
PMID

Rajala K, Pekkanen-Mattila M, Aalto-Setälä K
Cardiac differentiation of pluripotent stem cells.
Stem Cells Int 2011 ;2011383709
PMID

Frantzén J, Pälli A, Kotilainen E, Heino H, Mannerström B, Huhtala H, Kuokkanen H, Sándor GK, Leino K, Röyttä M, Parkkola R, Suuronen R, Miettinen S, Aro HT, Haimi S
In Vivo and In Vitro Study of a Polylactide-Fiber-Reinforced β-Tricalcium Phosphate Composite Cage in an Ovine Anterior Cervical Intercorporal Fusion Model.
Int J Biomater 2011 ;2011109638
PMID

Tirkkonen L, Halonen H, Hyttinen J, Kuokkanen H, Sievänen H, Koivisto AM, Mannerström B, Sándor GK, Suuronen R, Miettinen S, Haimi S
The effects of vibration loading on adipose stem cell number, viability and differentiation towards bone-forming cells.
J R Soc Interface 2011 ;8(65)1736-47
PMID

Thesleff T, Lehtimäki K, Niskakangas T, Mannerström B, Miettinen S, Suuronen R, Öhman J
Cranioplasty with adipose-derived stem cells and biomaterial: a novel method for cranial reconstruction.
Neurosurgery 2011 ;68(6)1535-40
PMID

Sartoneva R, Haimi S, Miettinen S, Mannerström B, Haaparanta AM, Sándor GK, Kellomäki M, Suuronen R, Lahdes-Vasama T
Comparison of a poly-L-lactide-co-ε-caprolactone and human amniotic membrane for urothelium tissue engineering applications.
J R Soc Interface 2011 ;8(58)671-7
PMID

Lindroos B, Suuronen R, Miettinen S
The potential of adipose stem cells in regenerative medicine.
Stem Cell Rev 2011 ;7(2)269-91
PMID

Sundberg M, Hyysalo A, Skottman H, Shin S, Vemuri M, Suuronen R, Narkilahti S
A xeno-free culturing protocol for pluripotent stem cell-derived oligodendrocyte precursor cell production.
Regen Med 2011 ;6(4)449-60
PMID

Shalaby A, Mennander A, Rinne T, Oksala N, Aanismaa R, Narkilahti S, Paavonen T, Laurikka J, Tarkka M
Aquaporin-7 expression during coronary artery bypass grafting with diazoxide.
Scand Cardiovasc J 2011 ;45(6)354-9
PMID

Vaajasaari H, Ilmarinen T, Juuti-Uusitalo K, Rajala K, Onnela N, Narkilahti S, Suuronen R, Hyttinen J, Uusitalo H, Skottman H
Toward the defined and xeno-free differentiation of functional human pluripotent stem cell-derived retinal pigment epithelial cells.
Mol Vis 2011 ;17558-75
PMID

, Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, Baker J, Baker D, Munoz MB, Beil S, Benvenisty N, Ben-Yosef D, Biancotti JC, Bosman A, Brena RM, Brison D, Caisander G, Camarasa MV, Chen J, Chiao E, Choi YM, Choo AB, Collins D, Colman A, Crook JM, Daley GQ, Dalton A, De Sousa PA, Denning C, Downie J, Dvorak P, Montgomery KD, Feki A, Ford A, Fox V, Fraga AM, Frumkin T, Ge L, Gokhale PJ, Golan-Lev T, Gourabi H, Gropp M, Lu G, Hampl A, Harron K, Healy L, Herath W, Holm F, Hovatta O, Hyllner J, Inamdar MS, Irwanto AK, Ishii T, Jaconi M, Jin Y, Kimber S, Kiselev S, Knowles BB, Kopper O, Kukharenko V, Kuliev A, Lagarkova MA, Laird PW, Lako M, Laslett AL, Lavon N, Lee DR, Lee JE, Li C, Lim LS, Ludwig TE, Ma Y, Maltby E, Mateizel I, Mayshar Y, Mileikovsky M, Minger SL, Miyazaki T, Moon SY, Moore H, Mummery C, Nagy A, Nakatsuji N, Narwani K, Oh SK, Oh SK, Olson C, Otonkoski T, Pan F, Park IH, Pells S, Pera MF, Pereira LV, Qi O, Raj GS, Reubinoff B, Robins A, Robson P, Rossant J, Salekdeh GH, Schulz TC, Sermon K, Sheik Mohamed J, Shen H, Sherrer E, Sidhu K, Sivarajah S, Skottman H, Spits C, Stacey GN, Strehl R, Strelchenko N, Suemori H, Sun B, Suuronen R, Takahashi K, Tuuri T, Venu P, Verlinsky Y, Ward-van Oostwaard D, Weisenberger DJ, Wu Y, Yamanaka S, Young L, Zhou Q
Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage.
Nat Biotechnol 2011 ;29(12)1132-44
PMID

Sundberg M, Hyysalo A, Skottman H, Shin S, Vemuri M, Suuronen R, Narkilahti S
A xeno-free culturing protocol for pluripotent stem cell-derived oligodendrocyte precursor cell production.
Regen Med 2011 ;6(4)449-60
PMID

Vaajasaari H, Ilmarinen T, Juuti-Uusitalo K, Rajala K, Onnela N, Narkilahti S, Suuronen R, Hyttinen J, Uusitalo H, Skottman H
Toward the defined and xeno-free differentiation of functional human pluripotent stem cell-derived retinal pigment epithelial cells.
Mol Vis 2011 ;17558-75
PMID

 
BioMediTech
Biokatu 8, 12
33520 Tampere, Finland
Maintained by: webmaster@biomeditech.fi
Last update: 12.8.2014 10.54 Muokkaa

University of Tampere
+358 3 355 111
registry@uta.fi

THE UNIVERSITY
Introduction
Admissions
Studies
Research
Contact information

CURRENT ISSUES
Coming events
Research News
Study News
Vacancies
» more

SERVICES
Administration
Career Services
Finnish Social Science Data Archive
International Office
IT services
Language Centre
Language Services
Library
Registrar's Office
Registry
Sports Activities
» more

STUDIES
Teaching schedules
Curricula guides
Unipoli Tampere
» more

ONLINE SERVICES
UTA intranet
Office 365 webmail
Uta webmail
Moodle
NettiOpsu
NettiKatti
Nelli
TamPub
Tamcat
Electronic exam service
Examination results